Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

NYC Orthodontist, Olga Bukholts, DDS, Announces Implementation of AI-Based Dental Monitoring System

[ad_1]

Perfect Smiles Orthodontics - Olga Bukholts, DDS

Perfect Smiles Orthodontics – Olga Bukholts, DDS

The DentalMonitoring technology allows me to follow my patients’ weekly progress without having to see them in the office. It saves the patient’s appointment time, while also giving me better control of each case.

Perfect Smiles Orthodontics (https://www.orthodontist-ny.com), located on the Upper West Side of Manhattan (New York), spearheaded by top-rated NYC orthodontist, Olga Bukholts, DDS, announced today that the Invisalign® and braces orthodontic specialty practice now offers DentalMonitoring – a revolutionary remote patient monitoring system that tracks patient orthodontic progress through weekly teeth photo capture and AI-based alerts that notify the orthodontist of any issues.

DentalMonitoring ensures compliance and helps the orthodontic team catch problems early – which ultimately decreases treatment time, as well as the number of office visits required. Patients also have the opportunity to track their Invisalign® or braces progress remotely using a secure mobile app.

Dr. Bukholts stated, “The DentalMonitoring technology allows me to follow my patients’ weekly progress without having to see them in the office. It saves the patient’s appointment time, while also giving me better control of each case.”

The best-in-class orthodontic team and dedicated staff of Perfect Smiles Orthodontics understand the concerns associated with visiting a dentist’s office in a post-pandemic world, which is why the specialty Invisalign® and braces orthodontic practice now offers DentalMonitoring to reduce in-office visits and overall treatment time. DentalMonitoring at Perfect Smiles Orthodontics utilizes patented technology to communicate and monitor patients’ orthodontic progress through a secure platform, from anywhere in the world.

A report by the U.S. Department of Health & Human Services emphasizes the drastic increase in remote healthcare visits since the beginning of the COVID-19 pandemic in 2020, which is why the Manhattan based Perfect Smiles Orthodontics (Upper West Side, NY) practice now offers DentalMonitoring, as it is of the utmost importance to provide patients access to safe and convenient healthcare resources.

The orthodontists of Perfect Smiles Orthodontics offer a variety of adult, children, and teen solutions for Invisalign®, clear aligners, and braces. The NYC orthodontic practice strives to provide patients with top-rated care and comfort in a concierge environment. Dr. Bukholts is an orthodontic braces and Invisalign® specialist who has treated thousands of patients. The Upper West Side practice is a longtime trusted staple in orthodontic care in the Upper Manhattan community for over 25 years.

About Us

Our best-in-class Upper West Side NYC orthodontist, Olga Bukholts, DDS, prides herself with providing patients with highly personalized and comprehensive orthodontic care before, during, and after an orthodontic treatment. Her philosophy of direct orthodontist to patient care at every visit has made Perfect Smiles Orthodontics one of the most trusted and respected practices in NYC. Dr. Bukholts uses the latest orthodontic braces and techniques to provide the best and quickest results possible. Last sentences needs a plural. For more information about customized orthodontic braces treatments, please contact our Upper West Side orthodontic practice:

Perfect Smiles Orthodontics

263 West End Ave, #1A

New York, NY 10023

(646) 368-1819

https://www.orthodontist-ny.com

Share article on social media or email:

[ad_2]

Health-E Commerce debunks Flexible Spending Account (FSA) myths in preparation for December 31 use-it-or-lose-it deadline

[ad_1]

Many consumers – and even many employers – do not realize that the COVID-inspired FSA extensions expire in December, which makes it critical this year for account holders to understand what their deadline is, how much they have remaining in their accounts and if they have a rollover or grace period.

More than 30 million Americans are enrolled in flexible spending accounts (FSAs), but most are not aware of what their spending deadline is or how to use these tax-advantaged funds. As employers across the country are conducting open enrollment meetings for 2023 health benefits, now is the perfect time to educate individuals and families about FSAs and to debunk some common myths that may cause consumers to miss out on the tax advantages of enrolling in an FSA or – worse yet – lose their hard-earned healthcare dollars to a missed deadline.

Health-E Commerce, parent brand to FSAstore.com, the first and leading online marketplace that sells exclusively FSA-eligible products, is on a mission to educate account holders about these myths so they can use, not lose, their FSA funds before the December 31 deadline.

“Many consumers – and even many employers – do not realize that the COVID-inspired FSA extensions expire in December, which makes it critical this year for account holders to understand what their deadline is, how much they have remaining in their accounts, and if they have a rollover or grace period option,” said Preston Farrington, CEO of Health-E Commerce. “By dispelling these myths and educating consumers about FSA rules, our team at Health-E Commerce is helping consumers get the most out of their tax-free healthcare dollars.”

4 FSA myth busters to help consumers make smart money moves


  • Myth #1: The COVID rule changes got rid of the FSA use-it-or-lose-it deadline.
  • Fact: FSA deadline extensions introduced during COVID were temporary, and not all employers adopted those options. In addition, the FSA deadline extension expires this year, which means the December 31 deadline – the date by which most whose health benefits run on a calendar year must spend FSA funds to avoid forfeiture – is back in play this year. For consumers who have a December 31, 2022 spending deadline and an FSA grace period, March 15, 2023 is the last chance to spend remaining 2022 FSA funds. For consumers who had the extended grace period offered for their 2021 FSA plan year, you may have until December 31, 2022 to spend down remaining 2021 FSA dollars.
  • Myth #2: It doesn’t matter if I miss the December 31 deadline, because all FSAs now have a rollover.
  • Fact: Only some FSAs have a rollover or carryover of funds. On top of that, temporary increases to the FSA carryover limits that were introduced during COVID are expiring, which means that $570 is the maximum amount an account holder with a carryover option is allowed to roll over into 2023, and anything over that amount will be forfeited. Account holders who had the luxury of rolling over all remaining FSA dollars for the past two years may have more money than ever remaining in their FSAs to spend before the deadline this year.
  • Myth #3: I can only use my FSA for a limited number of expenses, like vision and dental care.
  • Fact: While an employer can offer a limited-purpose FSA for vision and dental, the more common general medical FSA typically covers a wide variety of eligible expenses, including everyday health and wellness products and clinical services. FSA Store offers the industry’s most comprehensive eligibility list, with thousands of eligible products and services.
  • Myth #4: It doesn’t pay to enroll in an FSA if I’m just going to lose my money.
  • Fact: Contributing to an FSA allows consumers to reduce their taxable income, which is always a smart money move. In fact, by contributing tax-free FSA funds toward healthcare needs, individuals can save an estimated 30% (based on individual federal and state tax brackets). This is more important than ever as persistent inflation is driving up costs for nearly all goods and services. Plus, with easy-to-use tools that help account holders project tax savings and map out healthcare spending needs, receive reminders about their personal deadline, and quickly and easily shop for the latest FSA-eligible products, FSAstore.com helps account holders become savvy healthcare consumers and avoid losing FSA funds.

Health-E Commerce data suggests that over $1 billion in FSA dollars could have been forfeited in prior years and is dedicated to helping to ensure that never happens again. To mitigate potential forfeitures, Health-E Commerce is urging FSA users to check with their account administrator to understand if their employer offered any of these extensions and, if so, how much money they have remaining in their FSA from the 2021 and 2022 plan years to get the full picture of what they must spend by December 31. To learn more, visit FSAstore.com, and take advantage of the FSA Learning Center.

###

About Health-E Commerce

Health-E Commerce is the parent brand to FSA Store, HSAStore and WellDeservedHealth, a family of online marketplaces that serve the 70+ million consumers enrolled in pre-tax health and wellness accounts. The company also created Caring Mill, a popular private-label line of health products that benefits Children’s Health Fund and enables customers to make a donation with each purchase. Since 2010, the Health-E Commerce brands have led the direct-to-consumer e-commerce market for exclusively pre-tax health and wellness benefits. Health-E Commerce plays an essential role in expanding product eligibility for important new categories within the list of eligible medical expenses.

Share article on social media or email:

[ad_2]

AllerPops Completes Enrolment in Phase II Clinical Trial; Results Expected by October 21st, 2022.

[ad_1]

News Image

“We pride ourselves in our ability to meet the recruitment needs of all of our clinical trial sponsors, offering a state-of-the-art clinical research clinic strategically located in the heart of Toronto,” said Peter Wowjewnik, Partner at dicentra.

dicentra, a world-renowned Contract Research Organization (CRO) and global consulting firm are proud to congratulate their client, Allerpops, for recently completing enrolment for their phase II clinical trial on allergic rhinitis. The 72 healthy participants volunteered at dicentra’s clinical research site in Toronto, Canada.

dicentra’s Toronto site allowed for fast recruitment of participants due to its downtown location being located on multiple transit routes, providing access to millions of potential participants within a 20-mile radius. dicentra prides itself on having the capacity to recruit participants quickly to meet the needs of clinical trial sponsors, offering a state-of-the-art clinical research clinic strategically located in the heart of Toronto, Canada.

According to the The American Academy of Allergy, Asthma & Immunology (AAAAI), allergic rhinitis, also known as nasal allergies, hay fever, or seasonal allergies, affects between 10% to 30% of the global population. Despite this high prevalence, the etiology and pathophysiology of allergic rhinitis are complex and many cases often go undiagnosed or misdiagnosed. Allergic rhinitis is characterized by a number of symptoms including sneezing, runny nose, itching, and nasal congestion.

This phase II trial marks the first clinical trial for AllerPops, a Los-Alamos-based company dedicated to relieving nasal allergies (allergic rhinitis). The trial, described as a randomized, double-blind, controlled, single-centre, 21-day study, received approval from Health Canada in March of 2022. The trial’s objective is to assess the efficacy and safety of the investigational product AllerPops on nasal allergy symptoms.

“We want to congratulate AllerPops on pursuing this clinical trial and are proud to be a part of fast-tracking a truly innovative concept that intends to address people suffering from allergies,” says Peter Wojewnik, Partner at dicentra. “We pride ourselves in our ability to meet the recruitment needs of all of our clinical trial sponsors, offering a state-of-the-art clinical research clinic strategically located in the heart of Toronto, Canada.”

“It was very important to understand the sponsor’s expectations and vision. Experts from multiple departments stepped in to brainstorm and strategize the most efficient regulatory pathway that will also meet the sponsor’s long-term goals,” says Priyanka Bhatt, Project Manager at dicentra. “The product is a breakthrough concept and we are very happy to be able to bring the Sponsor’s vision to fruition! After all, this is what happens at dicentra, we accelerate innovation!”

“This trial was an important instrument to grow our business. I am glad to have had dicentra conduct the clinical trial.” Said Dr. Cliff Shunsheng Han, the founder of AllerPops, “Their expertise in trial design and government regulations allowed the trial creation process to pass much smoother than expected. Their experience and resources also guaranteed the timely completion of participant enrollment.”

Results from this clinical trial are expected by October 21st, 2022.

About Allerpops

Allerpops Corp. is a Los Alamos-based company dedicated to relieving allergies for long periods, removing the need for daily shots or pills. The company’s guiding principle is reconnecting customers with nature and the world. https://allerpops.com/

About dicentra

dicentra is a leading Contract Research Organization (CRO) and global consulting firm that specializes in addressing all matters related to safety, quality, and compliance for all product categories in the life sciences and food industries. We evaluate, implement, and provide all the necessary support for products and operations to gain market access and build confidence in your brand. We achieve this through our three business divisions: consulting, clinical trials, and certifications. Since our inception in 2002, we have completed over 24,000 projects and serviced over 1,400 companies internationally. https://dicentra.com/

Share article on social media or email:

[ad_2]

Final Call To Apply For The 2022 Biocodex Microbiota Foundation $50,000 U.S. Research Grant

[ad_1]

News Image

The Biocodex Microbiota Foundation is calling for final grant applications from early-career investigators studying gut microbiota in human health and disease. The $50,000 research grant can be applied to a new or existing study. The entry deadline is October 1, 2022, 5PM EST.

With the submission deadline approaching, the Biocodex Microbiota Foundation is calling for final grant applications from early-career investigators studying gut microbiota in human health and disease, including Covid-19, sleep disorders, the brain-gut axis and other evolving gut health research. The $50,000 research grant, now in its 6th year, is juried by a panel of medical and scientific experts in the field and can be applied to a new or existing study. The application can be downloaded here and deadline for entry is October 1, 2022, 5PM EST.

This is the sixth consecutive year the Biocodex Microbiota Foundation has awarded the $50,000 US grant, which aims to advance research and understanding of human microbiota.

“The study of the gut microbiota and its role in human health and disease is crucial for understanding the connections of the gut with the rest of the body, along with the discovery of novel health management solutions for these conditions,” says Julien Dureisseix, General Manager of Biocodex, Inc. “The Biocodex Microbiota Foundation’s mission is to help advance research and deepen the understanding of human microbiota. We at Biocodex are excited to continue the tradition of supporting up and coming researchers in this field.”

Julia Brown, MD, PhD., who is currently a Postdoctoral Associate in Pediatrics at Weill Cornell Medical College, received the 2021 grant to help further her research into the neonatal gut microbiome and its role in lung immune development and antiviral immunity.

“The Biocodex Microbiota Foundation grant has helped further the efforts to understand how the microbiome contributes to the heightened risks of severe RSV in preterm infants by dysregulating the immune response,” Dr. Brown explains. “We are currently working to identify specific bacteria or metabolites that are responsible for these effects, which could potentially offer therapeutic strategies to improve immune function in preterm infants by manipulating the microbiome.”

Other Biocodex Microbiota Foundation $50,000 grant recipients include:

  • 2020 — Dr. Jessica Queen, MD, PhD, for her work on Fusobacterium strains from colon cancer biopsies
  • 2019 — Dr. Arpana Gupta, PhD., for her research on the prevalence of Metabolic Syndrome (MetS)
  • 2018 — Dr. Tao Yang, PhD., for his investigation into how intestinal microbes may cause dysfunctional gut-brain connections
  • 2017 — Dr. Rashim Singh, PhD, for her research on flavonoids and microbiome interactions via triple recycling and their roles in food-borne carcinogen-induced colorectal cancer

The Biocodex Microbiota Foundation’s annual call for grant applications is part of a multi-year research initiative to recognize the interaction between microbiota and different pathologies. The 2022 applications will be reviewed, and recipient selected, by the US Biocodex Microbiota Foundation’s scientific board, comprised of Dr. Ruth Ann Luna from Texas Children’s Hospital and Baylor College of Medicine, Dr. Emeran Mayer from University of California Los Angeles (UCLA), and Dr. Erica Sonnenburg from Stanford University.

The ideal applicant is a US-based researcher with five or less years of research experience within the microbiota field seeking to establish themselves as an independent researcher. All finalized applications must be sent to USAFoundation@biocodex.com by the October 1, 2022, 5 p.m. EST deadline. Late or incomplete applications, or those that don’t meet the criteria of the grant program or research topic will not be considered.

To learn more information about Biocodex Microbiota Foundation and the 2022 US grant program, click here.

About the Biocodex Microbiota Foundation:

The Biocodex Microbiota Foundation’s mission is to support research into microbiota and its interaction with various pathologies. Research is reinforced through grants given to projects that examine the implication of microbiota in human health. The Biocodex Microbiota Foundation supports both foundational and applied research, and projects are selected annually by a committee of independent scientists.

The foundation’s primary activity remains the awarding of annual grants to innovative scientific research projects that explore the structure and impact of microbiota. In addition, the foundation also runs and helps establish programs to improve our understanding of microbiota and disseminates this knowledge as widely as possible, including scientific communities and via public projects aimed to help improve human health.

The Biocodex Microbiota Foundation is a non-profit, general interest organization. For more information about the foundation’s international research grants, visit here.

Share article on social media or email:

[ad_2]

Get Real Health Joins Client UHSFT to Highlight New Milestones for My Medical Record

[ad_1]

News Image

We have had a front row seat to the growth of My Medical Record from a pathway-specific solution to a comprehensive tool across all demographics. – Robin Wiener

Get Real Health, a member of the CPSI (NASDAQ: CPSI) family of companies and a provider of comprehensive patient engagement tools, joins client University Hospital Southampton NHS Foundation Trust (UHSFT) in announcing the eight-year anniversary of Get Real Health’s digital personal health record, My Medical Record, as well as the latest deployment of the solution at North Bristol for post-treatment follow ups for prostate cancer patients.

My Medical Record, developed for UHSFT by Get Real Health, was introduced in 2014 as a tracker for prostate cancer patients. Aimed at increasing patient engagement and collaborative care to reduce demand on services, such as outpatient appointments, My Medical Record offers chronic disease management as well as communication with providers, appointment coordination and medication access through mobile or desktop devices.

“We have had a front row seat to the growth of My Medical Record from a pathway-specific solution to a comprehensive tool across all demographics,” said Robin Wiener, President of Get Real Health. “The enhancements and updates over the years are a testament not only to the flexibility of our products but also to UHSFT’s commitment to citizens’ access to health records and care collaboration.”

Coinciding with the eight-year milestone is the 20th deployment of My Medical Record within the NHS at North Bristol:

“My Medical Record is now a core part of our business and clinical strategies, and we aim to offer the service to all patients that have a relationship with us,” said Kevin Hamer, My Medical Record Programme Manager. “This is key in supporting a positive patient experience whilst also reducing the stress and workload for our busy clinical services.”

The award-winning solution boasts over 130,000 users throughout the NHS, with 15 additional deployments on the horizon for 2022 and 2023.

“This is why we do what we do,” says Wiener. “The awards and recognition for our solutions are certainly appreciated but the real reward is knowing that millions of people around the world are living better lives through our work with forward-thinking organizations like UHSFT. That’s what we focus on.”

About Get Real Health

Get Real Health combines a world of new information from patients, devices and apps with existing clinical data to help individuals and healthcare professionals engage and empower each other. By giving providers and patients the information and tools they need to work together, we help our customers meet their ever-changing patient engagement needs. We help our customers deliver value-based care, improve outcomes, activate patients, and increase patient loyalty and satisfaction, all while meeting regulatory requirements. Visit: http://www.getrealhealth.com.

About University Hospital Southampton NHS Foundation Trust

University Hospital Southampton NHS Foundation Trust provides services to approximately 2.2 million people living in Southampton and south Hampshire, plus specialist services such as neurosciences, cardiac services and children’s intensive care to more than 3.7 million people in central southern England and the Channel Islands.

UHSFT is also a major centre for teaching and research in association with the University of Southampton, and partners include the Medical Research Council and Wellcome Trust. Visit: http://www.uhs.nhs.uk/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified generally by the use of forward-looking terminology and words such as “expects,” “anticipates,” “estimates,” “believes,” “predicts,” “intends,” “plans,” “potential,” “may,” “continue,” “should,” “will” and words of comparable meaning. Without limiting the generality of the preceding statement, all statements in this press release relating to the future success of the partnership between Get Real Health and UHSFT are forward-looking statements. We caution investors that any such forward looking statements are only predictions and are not guarantees of future performance. Certain risks, uncertainties and other factors may cause actual results to differ materially from those projected in the forward looking statements. Such factors may include: the ability of the My Medical Record solution to continue to increase patient engagement and reduce demand on certain services; the impact of the ongoing COVID-19 pandemic and related economic disruptions which have materially affected CPSI’s revenue and could materially affect CPSI’s gross margin and income, as well as CPSI’s financial position and/or liquidity; federal, state and local government actions to address and contain the impact of COVID-19 and their impact on us and our hospital clients; operational disruptions and heightened cybersecurity risks due to a significant percentage of our workforce working remotely; saturation of our target market and hospital consolidations; unfavorable economic or market conditions that may cause a decline in spending for information technology and services; significant legislative and regulatory uncertainty in the healthcare industry; exposure to liability for failure to comply with regulatory requirements; competition with companies that have greater financial, technical and marketing resources than we have; potential future acquisitions that may be expensive, time consuming, and subject to other inherent risks; our ability to attract and retain qualified client service and support personnel; disruption from periodic restructuring of our sales force; potential inability to properly manage growth in new markets we may enter; exposure to numerous and often conflicting laws, regulations, policies, standards or other requirements through our international business activities; potential litigation against us; our reliance on an international workforce which exposes us to various business disruptions; potential failure to develop new products or enhance current products that keep pace with market demands; failure to develop new technology and products in response to market demands; failure of our products to function properly resulting in claims for medical and other losses; breaches of security and viruses in our systems resulting in customer claims against us and harm to our reputation; failure to maintain customer satisfaction through new product releases free of undetected errors or problems; failure to convince customers to migrate to current or future releases of our products; failure to maintain our margins and service rates; increase in the percentage of total revenues represented by service revenues, which have lower gross margins; exposure to liability in the event we provide inaccurate claims data to payors; exposure to liability claims arising out of the licensing of our software and provision of services; dependence on licenses of rights, products and services from third parties; misappropriation of our intellectual property rights and potential intellectual property claims and litigation against us; interruptions in our power supply and/or telecommunications capabilities, including those caused by natural disaster; general economic conditions, including changes in the financial and credit markets that may affect the availability and cost of credit to us or our customers; potential inability to secure additional financing on favorable terms to meet our future capital needs; our substantial indebtedness, and our ability to incur additional indebtedness in the future; pressures on cash flow to service our outstanding debt; restrictive terms of our credit agreement on our current and future operations; changes in and interpretations of financial accounting matters that govern the measurement of our performance; significant charges to earnings if our goodwill or intangible assets become impaired; fluctuations in quarterly financial performance due to, among other factors, timing of customer installations; volatility in our stock price; failure to maintain effective internal control over financial reporting; lack of employment or non-competition agreement with most of our key personnel; inherent limitations in our internal control over financial reporting; vulnerability to significant damage from natural disasters; market risks related to interest rate changes; and other risk factors described from time to time in our public releases and reports filed with the Securities and Exchange Commission, including, but not limited to, our most recent Annual Report on Form 10-K. Relative to our dividend policy, the payment of cash dividends is subject to the discretion of our Board of Directors and will be determined in light of then-current conditions, including our earnings, our leverage, our operations, our financial conditions, our capital requirements and other factors deemed relevant by our Board of Directors. In the future, our Board of Directors may change our dividend policy, including the frequency or amount of any dividend, in light of then-existing conditions. We also caution investors that the forward-looking information described herein represents our outlook only as of this date, and we undertake no obligation to update or revise any forward-looking statements to reflect events or developments after the date of this press release.

Share article on social media or email:

[ad_2]

Amy Wilhelmi Wins Daily Herald Suburban Business Entrepreneurial Excellence Award; St. Charles business owner was among several honorees this year

[ad_1]

Illinois-Based Licensed Marriage and Family Therapist Amy Wilhelmi wins the Daily Herald Suburban Business Entrepreneurial Excellence Award.

“I thank the Daily Herald Suburban Business for recognizing myself and Balance Wellness Collective for this award. Especially in the post-COVID era, making mental health visible and a priority in our community is extremely needed.”

Amy Wilhelmi, a St. Charles-based licensed marriage and family therapist, was one of several honorees honored during the Daily Herald Suburban Business’ 23rd annual Entrepreneurial Excellence Awards, in partnership with NAWBO Chicago. The awards were presented during a virtual ceremony on Sept. 22.

The awards recognize and build entrepreneurship in Cook County, DuPage County, Kane County, Lake County, McHenry County, and Will County. Honorees demonstrate the best traits of entrepreneurship, including willingness to take risks, drive, perseverance, and business creativity.

Wilhelmi is the founder of the Balance Wellness Collective, a therapy, and divorce mediation practice in St. Charles. She describes her business as an integrative and holistic mental health practice with professional therapists and natural health professionals on staff. Clientele includes children, couples and families, individuals with addiction, and the LGBTQ community.

The publication recognized Wilhelmi in the Growth category. This category is measured by how the entrepreneur has contributed to the growth of the company or organization. Honorees were also chosen for their active participation in local and regional business growth, their promotion of charitable and civic causes, and their work to build the region’s workforce and enhance its quality of life.

Wilhelmi, author of the new book “Make Mental Gains,” explained how her business, a pillar in the community for many years, had to institute changes after the pandemic.

“I thank the Daily Herald Suburban Business for recognizing myself and Balance Wellness Collective for this award,” she said. “Especially in the post-COVID era, making mental health visible and a priority in our community is extremely needed. We had to do a very quick pivot to telehealth virtual care, and now we’re on our way back to in-person sessions with full force and are here to continue to serve. This award is timely for visibility and best practice continued client care. We love what we do serving individuals, couples, children, adolescents, and families with 12 therapists on staff and hope we can continue to normalize mental health in a holistic and integrative person-centered way and make it accessible to everyone for years to come. We’re all about making mental gains.”

About Amy Wilhelmi:

Amy Wilhelmi is a successful multi-entrepreneur as the founder of Balance Wellness Collective and Ascension Mentality, business & performance coach at Strategic Voyages Business Consultants, and a licensed marriage and family therapist. As a speaker, author, and athlete, she is on a mission to become a global go-to thought leader in making mental health normalized, approachable, and accessible. She believes that everyone should go to therapy and it should be a lifestyle practice just like going to the gym, eating healthy, and getting enough sleep. Everyone has mental health struggles and challenges, and at Balance Wellness Collective, she focuses on changing your mentality and habits. For more information about Balance Wellness Collective, visit https://balancewellnesscollective.com/. For information about Amy Wilhelmi, visit https://amywilhelmi.com/. ###

Share article on social media or email:

[ad_2]

Aktiv Pharma Group to Participate in the FDA Emerging Technology Program

[ad_1]

Aktiv Pharma Group (Aktiv) announced today the acceptance of its novel glass-free, film-based flexible primary drug container (PDC) technology for sterile injectables named ARCH, into the US Food and Drug Administration (FDA) Emerging Technology Program (ETP). The ETP is a collaborative effort which supports the FDA’s mission to facilitate modernization in the pharmaceutical industry and helps pharmaceutical companies reduce the time and cost requirements of introducing new, innovative solutions.

The ETP will enable the FDA to establish better understanding of the unique aspects of film-based PDCs and use this insight to develop guidelines and regulations ahead of a broader adoption by the industry. It will also allow Aktiv to communicate with the FDA to create alignment on regulatory, technical, and scientific matters associated with gaining regulatory approvals for Aktiv’s products. “We are excited to participate in this important program and delighted that our technology was recognized by the Agency for its broad potential to improve quality and safety of sterile injectable products” said Patricia Brown, Aktiv’s VP of Quality and Regulatory.

ARCH uses high-barrier polymer films to provide superior performance and increased functionality over conventional glass packaging, either as substitute to vials or when incorporated into prefilled drug delivery systems. ARCH was developed by Aktiv to address potential interactions between biologics and glass-based containers, improve aseptic barriers, provide a superior solution for drugs that require reconstitution at the time of use, and create a foundation for more functional and user-friendly combination products.

The first products to feature the flexible ARCH containers are emergency-use autoinjectors currently being advanced to FDA approval. Aktiv’s autoinjector pipeline includes tranexamic acid (TXA), atropine, pralidoxime chloride (2-PAM), atropine/2-PAM dual-injection, and scopolamine. The flexible container is crucial for achieving the unprecedented ruggedness and reliability of the ARAI autoinjector platform. Aktiv is additionally developing a biologic combination product in collaboration with a leading biopharmaceutical company and planning new products with integrated reconstitution capability.

About Aktiv’s Emerging Technology

With the exception of ampules, conventional rigid containers necessitate drug contact materials other than glass, most commonly rubber in elastomeric stoppers/plungers. In prefilled syringes and autoinjectors, interior container walls are frequently coated with silicone to prevent plunger binding and to improve glide. These materials are especially problematic for biopharmaceuticals which are inherently unstable and prone to aggregation and adsorption. Headspace in rigid containers results in a liquid/gas interface that further reduces stability of biopharmaceutical products. By comparison, Aktiv’s flexible film containers do not rely on elastomeric stoppers or siliconized surfaces, reducing the number of drug contact materials to just one, and their headspace can be minimized or even eliminated. Instead of stoppers, Aktiv’s containers utilize permanent, physicochemically bonded film-film closure, which unlike physically mated closures maintains aseptic barrier integrity even at cryogenic temperatures.

One of the key features of Aktiv’s technology is that the flexible containers can be configured with multiple compartments to be merged at the time of use by peeling frangible seals separating them, which enables incorporating aseptic reconstitution/mixing capability into the container itself. This reduces the room for potential user errors and contamination associated with the practice of packaging lyophilized drugs and their diluents into separate vials. It also allows for significantly easier implementation of automated reconstitution/mixing in drug delivery devices.

About Aktiv’s ARAI Autoinjector Platform

The ARAI autoinjector has been developed by Aktiv as a next generation autoinjector platform to address the shortfalls of previous autoinjectors by improving usability, reliability, robustness, and drug stability. ARAI is a versatile platform that can deliver up to 5 ml dose volumes, perform intramuscular and subcutaneous injections, perform simultaneous injections of multiple separately contained drugs, and automatically reconstitute drugs formulated in dry form. Aktiv is currently expanding the ARAI platform to include a consumer market autoinjector for biologics that will feature the same reliability, robustness, and usability benefits in a smaller form factor and with added data connectivity.

About Aktiv

Aktiv is a vertically integrated specialty pharmaceutical company with combination products contract development and manufacturing organization (CDMO) capabilities, that is developing, manufacturing, and commercializing sterile injectable products in a portfolio of proprietary, value-added, glass-free prefilled delivery systems.

Aktiv continues establishing itself as a vertically integrated CDMO with unique combination product competencies specifically targeting biopharmaceuticals. The company’s facilities in Colorado include device development, chemistry, manufacturing and controls (CMC), and manufacturing equipment labs, as well as assembly rooms and sterile fill-finish suites operated under Good Manufacturing Practice (GMP).

Share article on social media or email:

[ad_2]

Ostomy Surgery Saves Lives; Ostomy Awareness Day is here to let more people know that

[ad_1]

Ostomies save the lives of trauma patients and those with cancer, IBD, and other conditions by allowing bodily waste to be rerouted through an abdominal stoma and into an ostomy pouch.

If your gallbladder or appendix could kill you unless it is removed, surgery likely comes as welcome news – ostomy surgery is not often thought of like that. People are often surprised to know you can live an active life without a colon, bladder, or large segments of the small intestine. Ostomies save the lives of trauma patients and those with cancer, IBD, and other conditions by allowing bodily waste to be rerouted through an abdominal stoma and into an ostomy pouch. Ostomy Awareness Day is October 1, 2022 and seeks to dispel myths about ostomy and continent diversion surgery and give a voice to the up to 1 million in the U.S. who go to the bathroom this way.

Modern medical devices and prosthetics are often celebrated. Think of an insulin pump for diabetes, a pacemaker to sustain the heart, and the new mobility possible from a prosthetic limb. An ostomy pouch is a classified prosthetic device designed to improve lives but is too often stigmatized or feared.

Ostomy patients may feel alone in the world and at risk of health complications without the standards of care and support advocated for by United Ostomy Associations of America, Inc. (UOAA). An examination of these best practices in ostomy care recently published in the Journal of Wound Ostomy Continence Nursing points to gaps in patient care. The findings make it clear that discussions on the emotional impact of surgery and access to educational materials need to be a more consistent part of ostomy care to achieve better patient outcomes.

Ostomy Awareness Day and this year’s motto that “Ostomies are Life-Savers” plays a central role in educating both the general public and medical professionals. The Run for Resilience Ostomy 5k is the day’s featured event and seeks to connect and empower ostomates across the United States. Participants have the chance to share their stories of resilience and raise ostomy awareness in their own communities. It’s also a critical funding source for UOAA’s mission to promote quality of life for patients nationwide.

Learn more at ostomy.org/ostomy-awareness-day and follow #OstomiesAreLifesavers and #OstomyDay2022 on social media to witness people of all ages embracing life with an ostomy and taking part in the #RunforResilience Ostomy 5k.

The Run for Resilience Ostomy 5k is the major fundraiser for UOAA, a national 501(c)(3) nonprofit. It is supported by Exclusive Diamond sponsor, Hollister Inc. and Platinum sponsor Convatec with additional support from Bronze sponsors Safe n Simple, Trio Ostomy Care, Osto-EZ-Vent (KEM Enterprises) and DripDrop.

Share article on social media or email:

[ad_2]

ProActive Physical Therapy Specialists Opens New Clinic in Bend

[ad_1]

News Image

“I am excited to be opening this new location in Bend, and to be a part of the PPTS team,” says Ocano. “This clinic is a great opportunity for us to meet the needs of our patients and offer excellent customer service/care to the Bend community.” – Warren Ocano, Bend Clinic Director

ProActive Physical Therapy Specialists (PPTS) is pleased to announce their newest clinic has opened today in Bend, OR. Located at 61470 S. Highway 97, Suite #3B, the clinic is PPTS’ 16th location.

Warren Ocano, PT, DPT, will serve as the Bend Clinic Director and primary treating physical therapist.

PPTS specializes in providing exceptional physical therapy through a combination of evidence-based practice, care excellence, and clinical excellence. Services offered by the Bend clinic will include a specialization in orthopedic conditions, both conservative and post-operative, and vestibular conditions.

“I am excited to be opening this new location in Bend, and to be a part of the PPTS team,” says Ocano. “This clinic is a great opportunity for us to meet the needs of our patients and offer excellent customer service/care to the Bend community. I look forward to helping the community work to achieve their optimal level of function.”

For more information about the new Bend clinic and a full list of PPTS’ services and offerings, please visit https://proactivepts.com/. To book an appointment with Warren, please call 541-508-5473.

###

About ProActive Physical Therapy Specialists

Proactive Physical Therapy Specialists (PPTS) is an Oregon and Washington State-based, private physical therapy practice group. As a proud member of the Confluent Health family, PPTS positively impacts patients’ lives by delivering the best care and results through proven research, innovative treatments and technologies, and an approach that treats patients like family. For more information, visit proactivepts.com, or find them on Facebook at @proactivewa.

Share article on social media or email:

[ad_2]

Boston IVF in Syracuse Welcomes Reproductive Endocrinologist Maximilian Klein, MD to its Syracuse Fertility Center Team

[ad_1]

fertility doctor in Syracuse

Maximilian Klein, MD

“My wife and I built our own family with the help of fertility treatments, so as both a former patient and a fertility doctor, I have a unique connection with each individual or couple who seeks my assistance.” – Maximilian Klein, MD

Boston IVF, one of the world’s most experienced fertility treatment providers, who has assisted in over 125,000 babies born since 1986, is pleased to announce that reproductive endocrinologist Maximilian Klein, MD (he/him) has joined its team and fertility center in Syracuse, NY.

The addition of Dr. Klein is encouraging news for individuals and couples in Syracuse and Central New York who wish to build a family through assisted reproductive technologies like IVF.

He joins Boston IVF in Syracuse from a leading Upstate New York fertility practice and brings a full range of expertise in reproductive technologies and treatments – including IUI, IVF, egg freezing, LGBTQIA+ fertility, oncofertility, single-parenting, PCOS, and more.

“My wife and I built our own family with the help of fertility treatments, so as both a former patient and a fertility doctor, I have a unique connection with each individual or couple who seeks my assistance,” said Dr. Klein. “Fertility treatments are stressful, emotional, and life-changing. Understanding the ups and downs of treatment on a personal and professional level drives me to do everything I possibly can to help my patients achieve their dreams of becoming a parent.”

In 2013, Dr. Klein was inducted into the Arnold P. Gold Foundation Gold Humanism Honor Society, an organization that recognizes individuals who exemplify clinical care and leadership.

He also held a longstanding role as a Clinical Instructor of OB/GYN at the University of Vermont, where he taught the next generation of fertility experts.

Boston IVF in Syracuse, located at 5792 Widewaters Parkway, is a full-service fertility center, complete with an innovative IVF laboratory and scientists who together optimize the fertility success rates of patients who wish to build a family. Boston IVF in Syracuse provides advanced reproductive care to patients throughout Central New York and surrounding regions, including Rochester, Binghamton, Ithaca, Utica, Oneonta, Cooperstown, and more.

“Boston IVF is thrilled to add a reproductive endocrinologist of Dr. Klein’s pedigree to our fertility center in Syracuse,” said David Stern, CEO of the Boston IVF Fertility Network. “Dr. Klein will be a mainstay in the Syracuse region and a trusted resource for exceptional reproductive care. This is nothing but great news for individuals who rely on fertility treatments in Syracuse to help build their families.”

In addition to the site in Syracuse, Boston IVF also offers a full-service fertility treatment and IVF center in Albany, NY – featuring award-winning fertility doctor Sonia Elguero, MD.

Board-certified in Obstetrics & Gynecology, Dr. Klein completed his medical degree from New York Medical College, his OB/GYN residency at Wake Forest School of Medicine, and his fellowship in reproductive endocrinology & infertility at The Robert Larner, M.D. College of Medicine at The University of Vermont.

To learn more about Dr. Klein, get fertility advice, or to schedule a consultation, visit Boston IVF in Syracuse.

ABOUT BOSTON IVF Boston IVF is one of the largest and most experienced fertility networks in the United States, with more than 125,000 babies born since 1986. Founded as one of the nation’s first private practice IVF centers, the Boston IVF network has grown to include over 30 reproductive endocrinologists across 30 centers throughout Massachusetts, Maine, New Hampshire, Rhode Island, Delaware, Idaho, Indiana, New York, Ohio, and Utah. A renowned innovator of reproductive technologies, advanced protocols, and cutting-edge research, Boston IVF has achieved numerous “firsts” in the field of reproductive care. Its scientific and research arm continues to pave the way for breakthroughs in fertility care and its accredited Reproductive Endocrinology and Infertility (REI) Fellowship Program has graduated numerous reproductive endocrinologists as part of its mission to train the next generation of fertility experts.

Share article on social media or email:

[ad_2]